Opening the window to better outcomes for patients
Cancer treatment shouldn’t make patients feel worse than the disease itself. Unfortunately, this is often the case. The potent activity of many cancer therapies is often accompanied by toxicity to healthy cells, as they cannot readily differentiate them from cancer cells.
At Window Therapeutics, we are opening windows for the patients who need them the most.
Through a targeted approach, we are developing breakthrough cancer therapeutics designed to penetrate and permeate into diseased tissue and exert activity specifically against cancer cells and not healthy ones.
Our proprietary Bottle-brush-Analogue-Macromonomer or ‘BAM’ technology opens the therapeutic windows of a wide range of drug classes by augmenting their activity by orders of magnitude, while at the same time dramatically diminishing their systemic toxicity.
Our proprietary Bottle-brush-Analogue-Macromonomer or ‘BAM’ technology opens the therapeutic windows of a wide range of drug classes.
BAM technology enables drugs to achieve their full therapeutic potential, offering clinicians and patients new, more numerous and more effective therapeutic regimens from the very outset of treatment. Through BAM technology, Window Therapeutics is overcoming the complexities of cancer with the aim to improve and extend lives of patients.
BAM Technology, Activating therapies in the Tumor Microenvironment and Cancer Cells
Cancer treatments are frequently double-edged swords. For any cancer diagnosis, clinicians are constantly balancing the urgency of selecting the most appropriate and potent therapies with a patient’s other health issues.
A further complication is that in many cancer diagnoses, the first therapies selected are the most crucial in achieving a favourable and durable treatment response. However, many of the most effective cancer therapies possess narrow dosing ranges where they can be effective without causing severe toxicity and damage to healthy tissues and organs.
This range is called the Therapeutic Window. If patients are older and/or have advanced cancers, the Therapeutic Window is exceptionally narrow for any dose without causing severe adverse events.
The Window Therapeutic BAC technology makes it possible to open wider the therapeutic window for many vulnerable patients populations.
Drug Development
Pipeline
We strategically apply our proprietary BAM technology to build a diverse pipeline of cancer therapeutics that can treat cancer through a multipronged approach. BAM technologies enable the re-engineering of molecularly targeted therapies, invention of new combination therapies, formulation of safer, more focused, immuno-therapeutics, including groundbreaking Biologic-Brush Conjugates.
Platform Partnerships
Opportunities
Window Therapeutics’ BAM technology is uniquely suited to optimize, de-risk and accelerate the development of pre-clinical, early or late-stage drug candidates from potential partner companies. Similarly, BAM technology can be applied to rehabilitate drug candidates which have encountered mid- to late-stage clinical trial failure following promising early-stage trial results. BAM technology can also enable efficient and timely life-cycle management for well-established, marketed drugs by offering potential new chemical entity (NCE) designations and 505(b)(1) or 505(b)(2) regulatory approval pathways.
Window Therapeutics combines the continuing advances in immune, cancer and genomic biology with leading edge chemistry technologies to develop therapeutic innovations for the deadliest blood and solid cancers.
Kenneth C. Anderson
Professor, Researcher and Clinician, Harvard Medical School & DFCI